VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
VRTX on Nasdaq
Shares outstanding
256,606,920
Price per share
$453.36
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
231,808,096
Total reported value
$90,697,858,094
% of total 13F portfolios
0.04%
Share change
-8,698,446
Value change
-$3,690,820,455
Number of holders
1,494
Price from insider filings
$453.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Capital World Investors 11% $14,470,577,412 28,739,975 Capital World Investors 31 Dec 2024
Capital Research Global Investors 5.7% $7,319,049,204 14,536,344 Capital Research Global Investors 31 Mar 2025
FMR LLC 3.6% $4,642,686,284 9,220,827 FMR LLC 31 Dec 2024

As of 30 Sep 2025, 1,494 institutional investors reported holding 231,808,096 shares of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX). This represents 90% of the company’s total 256,606,920 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Capital World Investors 10% 25,910,587 -9.8% 1.4% $10,147,738,320
VANGUARD GROUP INC 9.4% 24,216,865 +1% 0.14% $9,484,293,009
BlackRock, Inc. 8.7% 22,253,047 +1.7% 0.15% $8,715,183,579
Capital Research Global Investors 6.5% 16,553,281 +2.8% 1.2% $6,482,977,895
STATE STREET CORP 4.5% 11,606,000 -1.4% 0.16% $4,545,373,840
JPMORGAN CHASE & CO 2.5% 6,434,778 +9.6% 0.16% $2,520,139,212
GEODE CAPITAL MANAGEMENT, LLC 2.3% 5,973,745 +0.76% 0.15% $2,328,861,818
WELLINGTON MANAGEMENT GROUP LLP 1.9% 4,772,042 -0.86% 0.33% $1,868,922,529
Capital International Investors 1.8% 4,689,059 +78% 0.3% $1,836,550,135
ALLIANCEBERNSTEIN L.P. 1.8% 4,522,586 +3.3% 0.56% $1,771,225,581
LOOMIS SAYLES & CO L P 1.6% 4,122,128 +8.1% 1.9% $1,614,390,030
JENNISON ASSOCIATES LLC 1.3% 3,454,947 -44% 0.79% $1,353,095,435
FMR LLC 1.3% 3,303,768 -48% 0.07% $1,293,887,557
MORGAN STANLEY 1.2% 3,108,405 -6.7% 0.07% $1,217,377,330
PRICE T ROWE ASSOCIATES INC /MD/ 1.2% 3,043,805 -3.7% 0.13% $1,192,076,000
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 1.1% 2,887,117 -5.9% 0.25% $1,130,710,501
BANK OF AMERICA CORP /DE/ 1.1% 2,840,424 +1.2% 0.08% $1,112,423,583
Clearbridge Investments, LLC 1% 2,645,764 +73% 0.78% $1,036,186,872
NORTHERN TRUST CORP 1% 2,627,887 -1.2% 0.13% $1,029,185,665
AMERIPRISE FINANCIAL INC 0.89% 2,276,927 +4.4% 0.21% $891,743,515
VICTORY CAPITAL MANAGEMENT INC 0.88% 2,247,566 +4.3% 0.5% $787,317,055
JANUS HENDERSON GROUP PLC 0.83% 2,119,107 -19% 0.38% $829,903,522
Invesco Ltd. 0.82% 2,096,797 +5.7% 0.13% $821,189,454
Legal & General Group Plc 0.76% 1,952,297 +3.3% 0.17% $764,597,601
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.71% 1,829,931 +3.2% 0.11% $716,674,177

Institutional Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 3,690,433 $1,669,531,924 -$101,369,859 $453.36 285
2025 Q3 231,808,096 $90,697,858,094 -$3,690,820,455 $391.64 1,494
2025 Q2 240,735,835 $107,165,642,790 +$1,856,744,900 $445.20 1,543
2025 Q1 236,653,399 $114,743,267,144 +$569,969,794 $484.82 1,597
2024 Q4 236,056,630 $95,094,515,159 +$124,454,808 $402.70 1,542
2024 Q3 234,301,041 $108,951,765,309 -$108,863,209 $465.08 1,532
2024 Q2 234,132,938 $109,741,428,164 +$127,466,437 $468.72 1,538
2024 Q1 233,778,905 $97,614,728,920 -$351,588,308 $418.01 1,481
2023 Q4 234,732,281 $95,518,842,840 -$282,404,031 $406.89 1,430
2023 Q3 235,201,359 $81,839,440,920 -$491,731,898 $347.74 1,268
2023 Q2 236,903,503 $83,231,226,220 -$329,673,784 $351.91 1,270
2023 Q1 237,449,022 $74,800,726,409 +$551,796,768 $315.07 1,191
2022 Q4 237,264,020 $68,520,934,164 +$69,172,686 $288.78 1,206
2022 Q3 237,170,581 $68,704,605,708 +$746,235,756 $289.54 1,108
2022 Q2 234,049,687 $65,932,675,845 +$619,489,758 $281.79 1,093
2022 Q1 233,557,250 $60,872,369,529 +$1,115,223,036 $260.97 1,050
2021 Q4 229,577,277 $50,395,687,889 -$237,458,680 $219.60 1,015
2021 Q3 230,800,835 $41,840,598,359 -$222,800,189 $181.39 920
2021 Q2 232,062,084 $46,728,254,072 -$411,655,570 $201.63 961
2021 Q1 235,696,332 $50,611,371,510 -$676,555,551 $214.89 983
2020 Q4 238,859,796 $56,374,238,590 -$907,518,096 $236.34 952
2020 Q3 242,062,493 $65,824,669,920 -$146,259,561 $272.12 931
2020 Q2 242,428,011 $70,341,346,452 -$453,115,099 $290.31 949
2020 Q1 244,182,755 $58,075,410,564 +$196,877,946 $237.95 842
2019 Q4 243,469,587 $53,307,090,832 -$548,123,974 $218.95 801
2019 Q3 245,828,310 $41,645,081,563 +$11,091,504 $169.42 696
2019 Q2 245,761,916 $45,037,488,806 +$697,671,100 $183.38 706
2019 Q1 245,359,778 $45,126,400,894 +$339,461,201 $183.95 727
2018 Q4 243,404,158 $40,329,522,766 +$325,902,984 $165.71 690
2018 Q3 241,051,774 $46,450,620,394 +$73,088,499 $192.74 687
2018 Q2 241,039,338 $40,950,724,377 +$46,743,521 $169.96 682
2018 Q1 240,511,936 $39,191,663,333 +$165,476,417 $162.98 674
2017 Q4 239,681,066 $35,912,095,840 +$288,569,706 $149.86 637
2017 Q3 237,711,534 $36,110,677,595 +$313,167,858 $152.04 605
2017 Q2 236,016,217 $30,400,623,804 +$78,079,742 $128.87 569
2017 Q1 235,865,728 $25,790,913,428 +$2,166,564,931 $109.35 512
2016 Q4 236,349,218 $17,416,160,042 -$346,305,205 $73.67 470
2016 Q3 240,883,461 $20,998,584,687 +$86,246,858 $87.21 480
2016 Q2 239,982,115 $20,645,253,416 +$255,018,558 $86.02 473
2016 Q1 236,595,476 $18,805,795,173 -$180,672,437 $79.49 487
2015 Q4 234,502,647 $29,506,588,526 -$17,291,028 $125.83 510
2015 Q3 235,203,508 $24,493,775,645 +$667,231,333 $104.14 487
2015 Q2 230,096,138 $28,415,941,068 -$406,870,829 $123.48 496
2015 Q1 233,389,366 $27,539,570,108 +$443,200,071 $117.97 471
2014 Q4 229,712,105 $27,292,739,520 -$488,784,588 $118.80 467
2014 Q3 233,322,706 $26,203,942,928 +$763,613,344 $112.31 424
2014 Q2 227,000,681 $21,491,265,738 +$278,089,765 $94.68 405
2014 Q1 223,473,017 $15,797,763,300 +$100,431,175 $70.72 390